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ABSTRACT 
• Thromboxanes are abundantly present in the rat brain but their 
possible physiological functions in the brain are not known. The 
prostaglandin endoperoxide analogue U-46619 is a selective agonist of 
TxA2 receptors in many peripheral tissues. In the present study the 
·central cardiovascular and ventilatory effects of U-46619 were 
investigated in rats. In conscious spontaneously hypertensive rats 
(SHR) U-46619 (1-100 nmol/kg i.c.v.) induced a strong dose-related 
increase in blood pressure but had no significant effect on heart rate. 
In conscious normotensive rats (NR) neither blood pressure nor heart 
rate was significantly affected. Furthermore, U-46619 (0.1-100 nmol/kg 
i.c.v.) had no significant effect on blood pressure, heart rate or 
ventilation in urethane-anaesthetised NR . 
The results demonstrate an increased sensitivity of SHR to TxA2. 
INTRODUCTION 
Classical prostaglandins are known to induce strong increases in 
blood pressure and heart rate after administration into the central 
nervous system (2,3). Although thromboxanes are abundantly present in 
the rat brain (4), the central cardiovascular effects of TxA2 or its 
analogues have not been reporTed. 
U-46619 is an analogue of the endoperoxide PGH2 which stimulates 
selectively the receptors of TxA2 in many peripheral tissues (5,6), and 
has been reported to increase blood pressure after intravenous 
administration in dogs (7). In contrast to the classical 
prostaglandins, U-46619 had no thermal effects when injected into the 
rat anterior hypo thalamus (8). Intracerebroventricular (i.c.v.) 
administration of U-46619 caused hypothermia associated with vomItIng, 
increased frequency of respiration and ear skin vasodilatation in cats 
1) A preliminary report of this study has been presented at the 9th 
International Congress of Pharmacology, London 1984 (1). 
2) Present address: Orion Pharmaceutical Co., P.O. Box 65, 
SF-02101 Espoo, Finland. 
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(9). In rabbits U-46619 i.c.v. had no effect on body temperature, 
though an increase in the respiratory rate and sedation was observed 
(9). 
We now wanted to study the effects of U-46619 i.c.v. on blood 
pressure and heart rate both in the conscious spontaneously 
hypertensive (SHR) and normotensive Wistar (NR) rats. , In addition, the 
cardiovascular and ventilatory effects of U-46619 were examined in 
anaesthetised NR. 
MATERIALS AND METHODS 
Experiments on conscious rats: 
Male spontaneously hypertensive rats of Okamoto-Aoki strain 
(M~llegaards Avlslaboratorier, Denmark), 360-410 g, 6 months of age, 
and weight-matched normotensive WisLar-rats were used. The rats were 
accommodated to standard ambient conditions for at least one week 
before the surgery. 
One week before the experiments the rats were anaesthetised with 
ketamine (30-40 mg/rat i.p.) and xylazine (2 mg/rat i.m.). A 
polyethylene catheter was inserted into the left carotid arLery. The 
catheter was exteriorised at the nape of the neck and sealed until use. 
The right lateral ventricle of the brain was cannulated with a PE-20 
polyeLhylene cannula. The coordinates were relative to the bregma, 
L=1.0, AP=-3.0 and from the skull surface V=6.0 mm. After insertion of 
two sLainless steel anchoring screws dental cement was applied to 
secure the cannula in place. The intracerebroventricular injections 
were performed by the following way: A 26 ga needle was adhered to a 
PE-50 polyethylene catheter and the whole system was filled with the 
drug or conLrol solution to be infused. The needle was then attached 
to the i.c.v. cannula, and the 'desired amount (15 microliters) of the 
solution was allowed to flow slowly by the virtue of hydrostatic 
pressure. The blood pressure and heart rate were continuosly monitored 
while the rats were conscious and unrestrained in plastic boxes 
(26x20x13 cm). Increasing doses of U-46619 (1-100 nanomoles/kg) or 
vehicle were administered inLo the cerebral ventricles at 60 minutes 
intervals. The analysis and the follow-up of the experiment was 
carried out by a laboraLory computer (PDP 11/23 Digital Equipment 
Corp.). The proper position of the i.c.v. cannula was ascertained at 
the end of each experiment by an injection of dye (methylene blue) into 
the cerebral venLricles. 
Experiments on anaesthetised rats: 
Experiments on anaesthetised rats were performed as earlier 
described in deLail by Paakkari (10, 11). Urethane-anaesthetised male 
WisLar rats (200-220 g) received increasing doses of, U-46619 (0.1-100 
nmol/kg) or vehicle i.c.v. at 30 min intervals. Ventilation was 
monitored with a hot wire flow meter placed in connection with the 
Lracheal tube, and the blood pressure and heart rate were recorded from 
the left femoral arLery. The body temperature of the rats was kept 
conSLant with a thermostate controlled heating pad. 
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Figure 1. Effect of U-46619 i.c.v. on mean arterial pressure (MAP) in 
conscious rats. Increasing doses of U-46619 or vehicle were 
administered i.c.v. at 60 min intervals. Values represent means 
+S.E. N=8 in SHR treated with U-46619, n=7 in control SHR and n=5 in 
NR. The differences in the changes in MAP between SHR and its control 
group were significant at the two highest doses (p<0.05 and 0.001, 
respectively), and between SHR and NR at the highest dose 
(p<0.05). (ANOVA followed by the Bonferroni test.) 
Drugs used: 
The stock solution (10 mg/ml) of (15S)-hydroxy-11cx, 
9cx -(epoxymethano) prosta-5Z, 13E-dienoic acid (U-46619) from Dr. 
Pike, Upjohn Company, was made in absolute ethanol and stored at +4 C. 
The dilutions were made freshly before each experiment in 0.9 % (w/v) 
NaCl (saline) and kept on ice. The control animals received the same 
volume of the corresponding ethanol-saline vehicle as the drug 
solutions in each case. 
Statistical analysis of the results: 
For calculations of the areas under the curves the trapezoidal 
method was used. The results are expressed as means + S.E. and 
analysed by ANOVA for repeated measures followed by the Bonferroni test 
for multiple comparisons (BMDP statistical software for Burroughs large 
systems computers). 
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Figure 2. Effect of U-46619 i.c.v. on heart rate in conscious rats. 
Increasing doses of U-46619 or vehicle were administered i.c.v. at 60 
min intervals. Values represent means +S.E. N=8 in SHR treated with 
U-46619, n=7 in control SHR and n=5 in NR. The changes in heart rate 
were not statistically significant (ANOVA followed by the Bonferroni 
test) . 
RESULTS 
Effects of U-46619 in conscious rats: 
U-46619, 1-100 nmol/kg i.c.v., increased mean arterial pressure 
(MAP) dose-dependently in spontaneously hypertertensive rats (SHR) 
(n=8). No significant changes were seen in normotensive rats treated 
with U-46619 (NR, n=5) or in the SHR treated with the vehicle (SHRC, 
n=7). In Fig. 1 the data for SHR and NR is shown. After the dose of 
1 nmol/kg i.c.v. the increase in MAP in SHR lasted about 10 min while 
long-lasting responses (about 55 min) were observed after the doses of 
10 or 100 nmol/kg i.c.v. The maximum changes in MAP after the first 
dose were 22+5 mm Hg in SHR, -2+2 mm Hg in NR and 9+2 mm Hg in SHR 
which received vehicle. After the injection of 10 nmol/kg of U-46619 
i.c.v the maximum changes in MAP during 55 min postinjection were 28~6 
mm Hg, 3+3 mm Hg and 2+2 mm Hg (SHRC). The corresponding changes 
after 100 nmol/kg i.c.v. were 34 +8 mm Hg (SHR), 13+4 mm Hg (NR) and 
7+3 mm Hg (SHRC). - -
- U-46619 i.c.v. had no statistically significant effect on heart 
rate in either SHR or NR (Fig. 2). The maximal changes in heart rate 
after the i.c.v. injections of either U-46619 or vehicle in both SHR 
and NR were smaller than +40 beats/min. 
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Effects of U-46619 in urethane-anaesthetised rats: 
Administration of increasing doses of U-46619 (0.1-100 nrnol/kg) 
i.c.v. in urethane-anaesthetised NR had no significant effect on blood 
pressure, heart rate, ventilation rate or tidal volume. A slight 
increase in the ventilatory rate of about 40 vent/min was observed 
after the highest dose. This effect was, however, compensated by a 
simultaneous decrease in tidal volume. (Results not shown.) 
DISCUSSION 
The administration of U-46619, a selective TxA2 agonist, i.c.v. 
induced strong dose-related rises of blood pressure in SHR. The almost 
instant onset of the hypertensive effect suggests that the site of 
action is close to the ventricular space. However, U-46619 as a very 
lipid soluble agent is likely to cross the blood-brain barrier. 
Therefore, a peripheral site of action due to a leakage of the drug 
from the central nervous system cannot be totally excluded. 
In contrast to the cardiovascular effects of centrally 
administered classical pros tag land ins (2,3), the U-46619-induced 
pressor effect was not accompanied by tachycardia. ThUS, the central 
pressor response of U-46619 may, at least in part, be mediated by 
cerebral structures different from those activated by the classical 
prostaglandins. Since U-46619 is a TxA2-agonist in the peripheral 
tissues (5), its hypertensive effect after i.c.v. administration is 
likely to be due to an activation of the same type of receptors also in 
the central nervous system. 
U-46619 had no significant effect on blood pressure, heart rate or 
respiration in NR, anaesthetised or conscious. This finding is in 
agreement with the earlier reports by Hawk ins and Lipton (8) that 
U-46619 failed to stimulate the prostaglandin-sensitive 
thermoregulatory areas of the rat hypo thalamus or brain stem. The 
failure of NR to respond to the central administration of U-46619 
suggests that--the cerebral thromboxane system is rather inactive in the 
normotensive state. The strong hypertension induced by i.c.v. 
administration of this agent in SHR, on the other hand, suggests that 
cerebral structures responsive to thromboxanes have an increased 
sensitivity in the hypertensive state. 
In conclusion, the present results showed that U-46619, a 
selective TxA2 agonist in many peripheral tissues, is a potent 
hypertensive agent in SHR but not in NR. Therefore, a modulator role 
for the cerebral thromboxanes in the central cardiovascular control in 
SHR is suggested. 
ACKNOWLEDGEMENTS 
We thank Dr. John E. Pike of the Upjohn Laboratories for the 
generous supply of U-46619. The Skilful technical assistance of 
following persons: Mrs Helena Ekstrom, Mrs Anne Makinen and Mrs Riitta 
Oinonen is gratefully acknowledged. 
385 
1 • 
2. 
REFERENCES 
Siren A-L, Svartstrom-Fraser M, Paakkari I. 
effects of U-46619 in the spontaneously 
rat. 9th International Congress of Pharmacology 
Volunteer Abstracts 1298P. 
Cardiovascular 
hypertensive 
(London 1984), 
Chiu KY, Richardson JS. On the role of prostaglandins in brain 
mechanisms controlling blood pressure. Gen. Pharmac. 14: 553, 
1983. 
3. Siren A-L. Ceneral cardiovascular and thermal effects of 
arachidonic acid and some of its metabolites in rats. 
Acta Universitatis Ouluensis, 090, Pharmacol. Physiol.1982. 
D90, Pharmacol. Physiol.1982. 
4. Abdel-Halim MS, Hamberg M, Sjoqvist B, Anggard E. 
Identification of prostaglandin D2 as a major prostaglandin 
in homogenates of rat brain. Prostaglandins 14: 633,1977. 
5. Coleman RA, Humphrey PPA, Kennedy I, Levy GP, Lumley P. Comparison 
of the actions of U-46619, a prostaglandin H2-analogue, wieh 
those of prostaglandin H2 and thromboxane A2 on some isolated 
smooth muscle preparations. Br. J. Pharmacol. 73: 773,1981. 
6. Kennedy I, Coleman RA, Humphrey PPA, Levy GP, Lumley P. Studies 
on the characterisation of prostanoid receptors: A proposed 
classification. Prostaglandins 24: 667,1982. 
7. Rose JC, Kot PA, Ramwell PW, Doykos M., O'Neill WP. Cardiovascular 
responses to three prostaglandin endoperoxide analogs in the 
dog. Proc. Soc. Expel. BioI. Med. 153: 209,1976. 
8. Hawkins M, Lipeon JM. Analogs of endoperoxide precursors of 
prostaglandins: Failure to affect body temperature when injected 
into primary and secondary central temperature controls. 
Prostaglandins 13: 209,1977. 
9. Milton AS, Cremades-Campos A, Sawhney VK, Bichard A. Effects of 
prostacyclin, 6-oxo-PGF1 and endoperoxide analogues on the 
body temperature of cats and rabbits. p 87 in Thermoregulatory 
Mechanisms and Their Therapeutic Implications. 4th Int. Symp. 
on the Pharmacology of Thermoregulation, (B Cox, P Lomax, 
AS Milton, E Schonbaum eds.) Karger, Basel, 1980. 
10. Paakkari I. A simple method for the verification of a successful 
cannulation of the rat cerebral ventricles. Experientia 
36: 887,1980. 
11. Paakkari I. Computerized recording of ventilation, cardiovascular 
parameters, and body temperature in anesthetized rats. 
J. Pharmacol. Meth. 6: 97,1981. 
386 
